The NO/ONOO-cycle as the central cause of heart failure

International Journal of Molecular Sciences

Volumn 14, Issue 11, 2013, Pages 22274-22330

  Pall, Martin L ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Ca2+ receptors; Free radicals; Inflammatory biochemistry; Mitochondrial dysfunction; Nitrosative stress; Peroxynitrite; Reactive oxygen nitrogen species; Tetrahydrobiopterin oxidation

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADIPONECTIN; CALCIUM; CALPAIN; CARDIOLIPIN; CYTOKINE; ENDOTHELIN 1; FREE RADICAL; INDUCIBLE NITRIC OXIDE SYNTHASE; MANGANESE SUPEROXIDE DISMUTASE; MITOCHONDRIAL PROTEIN; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXYNITRITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SUPEROXIDE; TETRAHYDROBIOPTERIN;

APOPTOSIS; CALCIUM CELL LEVEL; CELL DEATH; CONGESTIVE CARDIOMYOPATHY; ELECTRON TRANSPORT; ENERGY METABOLISM; ENZYME ACTIVITY; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE; HUMAN; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; REVIEW; SYSTOLIC HEART FAILURE; VALVULAR HEART DISEASE;

ENDOTHELIN-1; HEART FAILURE; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; PEROXYNITROUS ACID; REACTIVE OXYGEN SPECIES; RHOA GTP-BINDING PROTEIN;

EID: 84887541654     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms141122274     Document Type: Review

References (284)

1. Pall, M. L. Pulmonary hypertension is a probable NO/ONOO-cycle disease: A review. ISRN Hypertens. 2013, 2013, 742418: 1-742418: 27.
2. Pall, M. L. Multiple Chemical Sensitivity: Toxicological Questions and Mechanisms. In General and Applied Toxicology, 3rd ed.; Ballantyne, B., Marrs, T. C., Syversen, T., Eds.; John Wiley & Sons: London, UK, 2009; pp. 2303-2352.
3. Pall, M. L. Explaining "Unexplained Illnesses": Disease Paradigm for Chronic Fatigue Syndrome, Multiple Chemical Sensitivity, Fibromyalgia, Post-Traumatic Stress Disorder, Gulf War Syndrome and Others; Harrington Park Press: New York, NY, USA, 2007.
4. Pall, M. L.; Bedient, S. A. The NO/ONOO-cycle as the etiological mechanism of tinnitus. Int. Tinnitus J. 2007, 13, 99-104.
5. Pall, M. L. Teufelskreis NO/ONOO--Zyklus, oxidaver Stress, mitochondriale, inflammatorische und neurologische Dysfunktion. Umw. Med. Ges. 2010, 23, 281-293.
6. Pall, M. L. How can we cure NO/ONOO-cycle diseases? Approaches to curing chronic fatigue syndrome/myalgic encephalomyelitis, fibromyalgia, multiple chemical sensitivity, Gulf War syndrome and possibly many others. Townsend Lett. 2010, Feb/Mar, 75-84.
7. Pall, M. L. Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome. Med. Hypotheses 2000, 54, 115-125.
8. Pall, M. L. NMDA sensitization and stimulation by peroxynitrite, nitric oxide and organic solvents as the mechanism of chemical sensitivity in multiple chemical sensitivity. FASEB J. 2002, 16, 1407-1417.
9. Pall, M. L. Nitric oxide synthase partial uncoupling as a key switching mechanism for the NO/ONOO-cycle. Med. Hypotheses 2007, 69, 821-825.
10. 2+ signaling and TRP cation channel activation in nervous system. J. Recept. Signal. Transduct. Res. 2012, 32, 134-141.
11. Pacher, P.; Liaudet, L.; Bai, P.; Mabley, J. G.; Kaminski, P. M.; Virág, L.; Deb, A.; Szabó, E.; Ungvári, Z.; Wolin, M. S.; et al. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 2003, 107, 896-904.
12. Okamoto, T.; Akaike, T.; Sawa, T.; Miyamoto, Y.; van der Vliet, A.; Maeda, H. Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J. Biol. Chem. 2001, 276, 29596-29602.
13. Lokuta, A. J.; Maertz, N. A.; Meethal, S. V.; Potter, K. T.; Kamp, T. J.; Valdivia, H. H.; Haworth, R. A. Increased nitration of sarcoplamic reticulum Ca2+-ATPase in human heart failure. Circulation 2005, 111, 988-995.
14. Lancel, S.; Qin, F.; Lennon, S. L.; Zhang, J.; Tong, X.; Mazzini, M. J.; Kang, Y. J.; Siwik, D. A.; Cohen, R. A.; Colucci, W. S. Oxidative posttranslational modifications mediate decreased SERCA activity and myocyte dysfunction in Galphaq-overexpressing mice. Circ. Res. 2010, 107, 228-232.
15. Mihm, M. J.; Coyle, C. M.; Schanbacher, B. L.; Weinstein, D. M.; Bauer, J. A. Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure. Cardiovasc. Res. 2001, 49, 798-807.
16. Lauzier, B.; Sicard, P.; Bouchot, O.; Delemasure, S.; Moreau, D.; Vergely, C.; Rochette, L. A peroxynitrite decomposition catalyst: FeTPPS confers cardioprotection during reperfusion after cardioplegic arrest in a working isolated rat heart model. Fundam. Clin. Pharmacol. 2007, 21, 173-180.
17. Eleuteri, E.; Magno, F.; Gnemmi, I.; Carbone, M.; Colombo, M.; la Rocca, G.; Anzalone, R.; Tarro Genta, F.; Zummo, G.; di Stephano, A.; et al. Role of oxidative and nitrosative stress biomarkers in chronic heart failure. Front. Biosci. 2009, 14, 2230-2237.
18. Bonilla, I. M.; Sridhar, A.; Nishijima, Y.; Györke, S.; Cardounel, A. J.; Carnes, C. A. Differential effects of the peroxynitrite donor, SIN-1, on atrial and ventricular myocyte electrophysiology. J. Cardiovasc. Pharmacol. 2013, 61, 401-407.
19. Ferdinandy, P.; Danial, H.; Ambrus, I.; Rothery, R. A.; Schulz, R. Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ. Res. 2000, 87, 241-247.
20. Kohr, M. J.; Wang, H.; Wheeler, D. G.; Velayutham, M.; Zweier, J. L.; Ziolo, M. T. Targeting of phospholamban by peroxynitrite decreases beta-adrenergic stimulation in cardiomyocytes. Cardiovasc. Res. 2008, 77, 353-361.
21. Ohama, T.; Brautigan, D. L. Endotoxin conditioning induces VCP/p97-mediated and inducible nitric-oxide synthase-dependent Tyr284 nitration in protein phosphatase 2A. J. Biol. Chem. 2010, 285, 8711-8718.
22. Katori, T.; Donzelli, S.; Tocchetti, C. G.; Miranda, K. M.; Cormaci, G.; Thomas, D. D.; Ketner, E. A.; Lee, M. J.; Mancardi, D.; Wink, D. A.; et al. Peroxynitrite and myocardial contractility: In vivo versus in vitro effects. Free Radic. Biol. Med. 2006, 41, 1606-1618.
23. Kohr, M. J.; Traynham, C. J.; Roof, S. R.; Davis, J. P.; Ziolo, M. T. cAMP-independent activation of protein kinase A by the peroxynitrite generator SIN-1 elicits positive inotropic effects in cardiomyocytes. J. Mol. Cell. Cardiol. 2010, 48, 645-648.
24. Paolocci, N.; Ekelund, U. E.; Isoda, T.; Ozaki, M.; Vandegaer, K.; Georgakopoulos, D.; Harrison, R. W.; Kass, D. A.; Hare, J. M. cGMP-independent inotropic effects of nitric oxide and peroxynitrite donors: Potential role for nitrosylation. Am. J. Physiol. Heart Circ. Physiol. 2000, 279, H1982-H1988.
25. Madej, E.; Folkes, L. K.; Wardman, P.; Czapski, G.; Goldstein, S. Thiyl radicals react with nitric oxide to form S-nitrosothiols with rate constants near the diffusion-controlled limit. Free Radic. Biol. Med. 2008, 44, 2013-2018.
26. Lancel, S.; Zhang, J.; Evangelista, A.; Trucillo, M. P.; Tong, X.; Siwik, D. A.; Cohen, R. A.; Colucci, W. S. Nitroxyl activates SERCA in cardiac myocytes via glutathiolation of cysteine 674. Circ. Res. 2009, 104, 720-723.
27. Daiber, A.; Oelze, M.; Coldewey, M.; Kaiser, K.; Huth, C.; Schildknecht, S.; Bachschmid, M.; Nazirisadeh, Y.; Ullrich, V.; Mülsch, A.; et al. Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. Biochem. Biophys. Res. Commun. 2005, 338, 1865-1874.
28. Lancel, S.; Tissier, S.; Mordon, S.; Marechal, X.; Depontieu, F.; Scherpereel, A.; Chopin, C.; Neviere, R. Peroxynitrite decomposition catalysts prevent myocardial dysfunction and inflammation in endotoxemic rats. J. Am. Coll. Cardiol. 2004, 43, 2348-2358.
29. Belch, J. J.; Bridges, A. B.; Scott, N.; Chopra, M. Oxygen free radicals and congestive heart failure. Br. Heart J. 1991, 65, 245-248.
30. Mallat, Z.; Philip, I.; Lebret, M.; Chatel, D.; Maclouf, J.; Tedgui, A. Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: A potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 1998, 97, 1536-1539.
31. Ide, T.; Tsutsui, H.; Kinugawa, S.; Suematsu, N.; Hayashidani, S.; Ichikawa, K.; Utsumi, H.; Machida, Y.; Egashira, K.; Takeshita, A. Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ. Res. 2000, 86, 152-157.
32. Sobotka, P. A.; Brottman, M. D.; Weitz, Z.; Birnbaum, A. J.; Skosey, J. L.; Zarling, E. J. Elevated breath pentane in heart failure reduced by free radical scavenger. Free Radic. Biol. Med. 1993, 14, 643-647.
33. Wolfram, R.; Oguogho, A.; Palumbo, B.; Sinzinger, H. Enhanced oxidative stress in coronary heart disease and chronic heart failure as indicated by an increased 8-epi-PGF(2alpha). Eur. J. Heart Fail. 2005, 7, 167-172.
34. Freeman, L. M.; Rush, J. E.; Milbury, P. E.; Blumberg, J. B. Antioxidant status and biomarkers of oxidative stress in dogs with congestive heart failure. J. Vet. Intern. Med. 2005, 19, 537-541.
35. Ide, T.; Tsutsui, H.; Kinugawa, S.; Utsumi, H.; Kang, D.; Hattori, N.; Uchida, K.; Arimura, K.; Egashira, K.; Takeshita, A. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ. Res. 1999, 85, 357-363.
36. Mak, S.; Newton, G. E. The oxidative stress hypothesis of congestive heart failure: Radical thoughts. Chest 2001, 120, 2035-2046.
37. Redout, E. M.; Wagner, M. J.; Zuidwijk, M. J.; Boer, C.; Musters, R. J.; van Hardeveld, C.; Paulus, W. J.; Simonides, W. S. Right-ventricular failure is associated with increased mitochondrial complex II activity and production of reactive oxygen species. Cardiovasc. Res. 2007, 75, 770-781.
38. Konorev, E. A.; Kennedy, M. C.; Kalyanaraman, B. Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: The role of reactive oxygen and nitrogen intermediates. Arch. Biochem. Biophys. 1999, 368, 421-428.
39. Faulk, A.; Weissig, V.; Elbayoumi, T. Mitochondria-specific nano-emulsified therapy for myocardial protection against Doxorubicin-induced cardiotoxicity. Methods Mol. Biol. 2013, 991, 99-112.
40. Melov, S.; Schneider, J. A.; Day, B. J.; Hinerfeld, D.; Coskun, P.; Mirra, S. S.; Crapo, J. D.; Wallace, D. C. A novel neurological phenotype in mice lacking mitochondrial manganese superoxide dismutase. Nat. Genet. 1998, 18, 159-163.
41. Nojiri, H.; Shimizu, T.; Funakoshi, M.; Yamaguchi, O.; Zhou, H.; Kawakami, S.; Ohta, Y.; Sami, M.; Tachibana, T.; Ishikawa, H.; et al. Oxidative stress causes heart failure with impaired mitochondrial respiration. J. Biol. Chem. 2006, 281, 33789-33801.
42. Kubin, A. M.; Skoumal, R.; Tavi, P.; Konyi, A.; Perjes, A.; Leskinen, H.; Ruskoaho, H.; Szokodi, I. Role of reactive oxygen species in regulation of cardiac contractility. J. Mol. Cell. Cardiol. 2011, 50, 884-893.
43. Ghosh, G.; De, K.; Maity, S.; Bandyopadhyay, D.; Bhattacharya, S.; Reiter, R. J.; Bandyopadhyay, A. Melatonin protects against oxidative damage and restores expression of GLUT4 gene in the hyperthyroid rat heart. J. Pineal Res. 2007, 42, 71-82.
44. Dai, D. F.; Hsieh, E. J.; Liu, Y.; Chen, T.; Beyer, R. P.; Chin, M. T.; MacCoss, M. J.; Rabinovitch, P. S. Mitochondrial proteome remodelling in pressure overload-induced heart failure: The role of mitochondrial oxidative stress. Cardiovasc. Res. 2012, 93, 79-88.
45. Matsushima, S.; Ide, T.; Yamato, M.; Matsusaka, H.; Hattori, F.; Ikeuchi, M.; Kubota, T.; Sunagawa, K.; Hasegawa, Y.; Kurihara, T.; et al. Overexpression of mitochondrial peroxiredoxin-3 prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation 2006, 113, 1779-1786.
46. Bryk, R.; Griffin, P.; Nathan, C. Peroxynitrite reductase activity of bacterial peroxiredoxins. Nature 2000, 407, 211-215.
47. Dubuisson, M.; Vander Stricht, D.; Clippe, A.; Etienne, F.; Nauser, T.; Kissner R.; Koppenol, W. H.; Rees, J. F.; Knoops, B. Human peroxiredoxin 5 is a peroxynitrite reductase. FEBS Lett. 2004, 571, 161-165.
48. Reinartz, M.; Ding, Z.; Flögel, U.; Gödecke, A.; Schrader, J. Nitrosative stress leads to protein glutathiolation, increased S-nitrosation, and up-regulation of peroxiredoxins in the heart. J. Biol. Chem. 2008, 283, 17440-17449.
49. Wang, S. B.; Murray, C. I.; Chung, H. S.; van Eyk, J. E. Redox regulation of mitochondrial ATP synthase. Trends Cardiovasc. Med. 2013, 23, 14-18.
50. Tsutsui, H.; Kinugawa, S.; Matsushima, S. Oxidative stress and mitochondrial DNA damage in heart failure. Circ. J. 2008, 72, A31-A37.
51. Sparagna, G. C.; Lesnefsky, E. J. Cardiolipin remodeling in the heart. J. Cardiovasc. Pharmacol. 2009, 53, 290-301.
52. Sparagna, G. C.; Chicco, A. J.; Murphy, R. C.; Bristow, M. R.; Johnson, C. A.; Rees, M. L.; Maxey, M. L.; McCune, S. A.; Moore, R. L. Loss of cardiac tetralinoleoyl cardiolipin in human and experimental heart failure. J. Lipid Res. 2007, 48, 1559-1570.
53. 2+ in mitochondrial dysfunction and disease. Cell Calcium 2009, 45, 643-650.
54. Tsutsui, H.; Kinugawa, S.; Matsushima, S. Mitochondrial oxidative stress and dysfunction in myocardial remodelling. Cardiovasc. Res. 2009, 81, 449-456.
55. Siveski-Iliskovic, N.; Hill, M.; Chow, D. A.; Singal, P. K. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 1995, 91, 10-15.
56. Rautiainen, S.; Levitan, E. B.; Mittleman, M. A.; Wolk, A. Total antioxidant capacity of diet and risk of heart failure: A population-based prospective cohort of women. Am. J. Med. 2013, 126, 494-500.
57. Korantzopoulos, P.; Galaris, D.; Papaioannides, D.; Siogas, K. The possible role of oxidative stress in heart failure and the potential of antioxidant intervention. Med. Sci. Monit. 2003, 9, RA120-RA125.
58. Castro, P.; Pérez, O.; Greig, D.; Díaz-Araya, G.; Moraga, F.; Chiong, M.; Troncoso, R.; Padilla, I.; Vukasovic, J. L.; Corbalán, R.; et al. Effects of carvedilol on functional capacity, left ventricular function, catecholamines and oxidative stress in patients with chronic heart failure. Rev. Esp. Cardiol. 2004, 57, 1053-1058 (in Spanish).
59. Witman, M. A.; McDaniel, J.; Fjeldstad, A. S.; Ives, S. J.; Zhao, J.; Nativi, J. N.; Stehlik, J.; Wray, D. W.; Richardson, R. S. A differing role of oxidative stress in the regulation of central and peripheral hemodynamics during exercise in heart failure. Am. J. Physiol. Heart Circ. Physiol. 2012, 303, H1237-H1244.
60. Wang, G.; Li, W.; Lu, X.; Bao, P.; Zhao, X. Luteolin ameliorates cardiac failure in type I diabetic cardiomyopathy. J. Diabetes Complicat. 2012, 26, 259-265.
61. Tanaka, T.; Ogawa, M.; Suzuki, J.; Sekinishi, A.; Itai, A.; Hirata, Y.; Nagai, R.; Isobe, M. Inhibition of IκB phosphorylation prevents load-induced cardiac dysfunction in mice. Am. J. Physiol. Heart Circ. Physiol. 2012, 303, H1435-H1445.
62. Cai, Y.; Yu, S. S.; Chen, T. T.; Gao, S.; Geng, B.; Yu, Y.; Ye, J. T.; Liu, P. Q. EGCG inhibits CTGF expression via blocking NF-κB activation in cardiac fibroblast. Phytomedicine 2013, 20, 106-113.
63. Maier, H. J.; Schips, T. G.; Wietelmann, A.; Krüger, M.; Brunner, C.; Sauter, M.; Klingel, K.; Böttger, T.; Braun, T.; Wirth, T. Cardiomyocyte-specific IκB kinase (IKK)/NF-κB activation induces reversible inflammatory cardiomyopathy and heart failure. Proc. Natl. Acad. Sci. USA 2012, 109, 11794-11799.
64. Purcell, N. H.; Tang, G.; Yu, C.; Mercurio, F.; DiDonato, J. A.; Lin, A. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc. Natl. Acad. Sci. USA 2001, 98, 6668-6673.
65. Li, Y.; Ha, T.; Gao, X.; Kelley, J.; Williams, D. L.; Browder, I. W.; Kao, R. L.; Li, C. NF-kappaB activation is required for the development of cardiac hypertrophy in vivo. Am. J. Physiol. Heart Circ. Physiol. 2004, 287, H1712-H1720.
66. Xu, Z.; Lin, S.; Wu, W.; Tan, H.; Wang, Z.; Cheng, C.; Lu, L.; Zhang, X. Ghrelin prevents doxorubicin-induced cardiotoxicity through TNF-alpha/NF-kappaB pathways and mitochondrial protective mechanisms. Toxicology 2008, 247, 133-138.
67. Xing, L.; Jiang, M.; Dong, L.; Gao, J.; Hou, Y.; Bai, G.; Luo, G. Cardioprotective effects of the YiQiFuMai injection and isolated compounds on attenuating chronic heart failure via NF-κB inactivation and cytokine suppression. J. Ethnopharmacol. 2013, 148, 239-245.
68. Ock, S.; Ahn, J.; Lee, S. H.; Park, H.; Son, J. W.; Oh, J. G.; Yang, D. K.; Lee, W. S.; Kim, H. S.; Rho, J.; et al. Receptor activator of nuclear factor-κB ligand is a novel inducer of myocardial inflammation. Cardiovasc. Res. 2012, 94, 105-114.
69. Del Vescovo, C. D.; Cotecchia, S.; Diviani, D. A-kinase-anchoring protein-Lbc anchors IκB kinase β to support interleukin-6-mediated cardiomyocyte hypertrophy. Mol. Cell. Biol. 2013, 33, 14-27.
70. Hamid, T.; Guo, S. Z.; Kingery, J. R.; Xiang, X.; Dawn, B.; Prabhu, S. D. Cardiomyocyte NF-κB p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. Cardiovasc. Res. 2011, 89, 129-138.
71. Borthwick, L. A.; Wynn, T. A.; Fisher, A. J. Cytokine mediated tissue fibrosis. Biochim. Biophys. Acta 2013, 1832, 1049-1060.
72. Finkel, M. S.; Oddis, C. V.; Jacob, T. D.; Watkins, S. C.; Hattler, B. G.; Simmons, R. L. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992, 257, 387-389.
73. Kubota, T.; McTiernan, C. F.; Frye, C. S.; Demetris, A. J.; Feldman, A. M. Cardiac-specific overexpression of tumor necrosis factor-alpha causes lethal myocarditis in transgenic mice. J. Card. Fail. 1997, 3, 117-124.
74. Kubota, T.; McTiernan, C. F.; Frye, C. S.; Slawson, S. E.; Lemster, B. H.; Koretsky, A. P.; Demetris, A. J.; Feldman, A. M. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ. Res. 1997, 81, 627-635.
75. Yajima, T.; Murofushi, Y.; Zhou, H.; Park, S.; Housman, J.; Zhong, Z. H.; Nakamura, M.; Machida, M.; Hwang, K. K.; Gu, Y.; et al. Absence of SOCS3 in the cardiomyocyte increases mortality in a gp130-dependent manner accompanied by contractile dysfunction and ventricular arrhythmias. Circulation 2011, 124, 2690-2701.
76. Ohmori, Y.; Schreiber, R. D.; Hamilton, T. A. Synergy between interferon-gamma and tumor necrosis factor-alpha in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kappaB. J. Biol. Chem. 1997, 272, 14899-14907.
77. Schulz, R.; Nava, E.; Moncada, S. Induction and potential biological relevance of a Ca2+-independent nitric oxide synthase in the myocardium. Br. J. Pharmacol. 1992, 105, 575-580.
78. Kalk, P.; Westermann, D.; Herzfeld, S.; Relle, K.; Pfab, T.; Bauer, C.; Tschöpe, C.; Stasch, J. P.; Hocher, B. Additional lack of iNOS attenuates diastolic dysfunction in aged ET-1 transgenic mice. Can. J. Physiol. Pharmacol. 2008, 86, 353-357.
79. Madonna, R.; Jiang, J.; Geng, Y. J. Attenuated expression of gelsolin in association with induction of aquaporin-1 and nitric oxide synthase in dysfunctional hearts of aging mice exposed to endotoxin. Int. J. Immunopathol. Pharmacol. 2012, 25, 911-922.
80. Tatsumi, T.; Akashi, K.; Keira, N.; Matoba, S.; Mano, A.; Shiraishi, J.; Yamanaka, S.; Kobara, M.; Hibino, N.; Hosokawa, S.; et al. Cytokine-induced nitric oxide inhibits mitochondrial energy production and induces myocardial dysfunction in endotoxin-treated rat hearts. J. Mol. Cell. Cardiol. 2004, 37, 775-784.
81. Motawi, T. K.; Darwish, H. A.; Abd El Tawab, A. M. The relative efficacy of aminoguanidine and pentoxifylline in modulating endotoxin-induced cardiac stress. Cell Biochem. Funct. 2011, 29, 694-702.
82. Panaro, M. A.; Pricci, M.; Meziani, F.; Ragot, T.; Andriantsitohaina, R.; Mitolo, V.; Tesse, A. Cyclooxygenase-2-derived prostacyclin protective role on endotoxin-induced mouse cardiomyocyte mortality. Cardiovasc. Toxicol. 2011, 11, 347-356.
83. Gödecke, A.; Molojavyi, A.; Heger, J.; Flögel, U.; Ding, Z.; Jacoby, C.; Schrader, J. Myoglobin protects the heart from inducible nitric-oxide synthase (iNOS)-mediated nitrosative stress. J. Biol. Chem. 2003, 278, 21761-21766.
84. Mungrue, I. N.; Gros, R.; You, X.; Pirani, A.; Azad, A.; Csont, T.; Schulz, R.; Butany, J.; Stewart, D. J.; Husain, M. Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J. Clin. Investig. 2002, 109, 735-743.
85. Drexler, H.; Kästner, S.; Strobel, A.; Studer, R.; Brodde, O. E.; Hasenfuss, G. Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. J. Am. Coll. Cardiol. 1998, 32, 955-963.
86. Haywood, G. A.; Tsao, P. S.; von der Leyen, H. E.; Mann, M. J.; Keeling, P. J.; Trindade, P. T.; Lewis, N. P.; Byrne, C. D.; Rickenbacher, P. R.; Bishopric, N. H.; et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996, 93, 1087-1094.
87. Dias, F. A. L.; Urboniene, D.; Wolska, B. M. Ablation of iNOS delays cardiac contractile dysfunction in chronic hypertension. Front. Biosci. 2010, 2, 312-324.
88. Damy, T.; Ratajczak, P.; Shah, A. M.; Camors, E.; Marty, I.; Hasenfuss, G.; Marotte, F.; Samuel, J. L.; Heymes, C. Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet 2004, 363, 1365-1367.
89. Winlaw, D. S.; Smythe, G. A.; Keogh, A. M.; Schyvens, C. G.; Spratt, P. M.; Macdonald, P. S. Increased nitric oxide production in heart failure. Lancet 1994, 344, 373-374.
90. Sugamori, T.; Ishibashi, Y.; Shimada, T.; Takahashi, N.; Sakane, T.; Ohata, S.; Kunizawa, Y.; Inoue, S.; Nakamura, K.; Ohta, Y.; et al. Increased nitric oxide in proportion to the severity of heart failure in patients with dilated cardiomyopathy: Close correlation of tumor necrosis factor-alpha with systemic and local production of nitric oxide. Circ. J. 2002, 66, 627-632.
91. Usui, M.; Matsuoka, H.; Miyazaki, H.; Ueda, S.; Okuda, S.; Imaizumi, T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci. 1998, 62, 2425-2430.
92. De Laforcade, A. M.; Freeman, L. M.; Rush, J. E. Serum nitrate and nitrite in dogs with spontaneous cardiac disease. J. Vet. Intern. Med. 2003, 17, 315-318.
93. Yu, C. M.; Fung, P. C.; Chan, G.; Lai, K. W.; Wang, Q.; Lau, C. P. Plasma nitric oxide level in heart failure secondary to left ventricular diastolic dysfunction. Am. J. Cardiol. 2001, 88, 867-870.
94. Bernstein, R. D.; Zhang, X.; Zhao, G.; Forfia, P.; Tuzman, J.; Ochoa, F.; Ochoa, M.; Vogel, T.; Hintze, T. H. Mechanisms of nitrate accumulation in plasma during pacing-induced heart failure in conscious dogs. Nitric Oxide 1997, 1, 386-396.
95. Kaye, D. M.; Chin-Dusting, J.; Esler, M. D.; Jennings, G. L. The failing human heart does not release nitrogen oxides. Life Sci. 1998, 62, 883-887.
96. Archer, S. Measurement of nitric oxide in biological models. FASEB J. 1993, 7, 349-360.
97. Murphy, M. E.; Noack, E. Nitric oxide assay using hemoglobin method. Methods Enzymol. 1994, 233, 240-250.
98. Rodnenkov, O. V.; Luneva, O. G.; Ulyanova, N. A.; Maksimov, G. V.; Rubin, A. B.; Orlov, S. N.; Chazov, E. I. Erythrocyte membrane fluidity and haemoglobin haemoporphyrin conformation: Features revealed in patients with heart failure. Pathophysiology 2005, 11, 209-213.
99. Sumino, H.; Sato, K.; Sakamaki, T.; Masuda, H.; Nakamura, T.; Kanda, T.; Nagai, R. Decreased basal production of nitric oxide in patients with heart disease. Chest 1998, 113, 317-322.
100. Katz, S. D.; Khan, T.; Zeballos, G. A.; Mathew, L.; Potharlanka, P.; Knecht, M.; Whelan, J. Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure. Circulation 1999, 99, 2113-2117.
101. Otani, H. The role of nitric oxide in myocardial repair and remodeling. Antioxid. Redox Signal. 2009, 11, 1913-1928.
102. McDonald, L. J.; Murad, F. Nitric oxide and cyclic GMP signaling. Proc. Soc. Exp. Biol. Med. 1996, 211, 1-6.
103. Francis, S. H.; Busch, J. L.; Corbin, J. D.; Sibley, D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol. Rev. 2010, 62, 525-563.
104. Pacher, P.; Beckman, J. S.; Liaudet, L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 2007, 87, 315-424.
105. Pryor, W. A.; Squadrito, G. L. The chemistry of peroxynitrite: A product from the reaction of nitric oxide with superoxide. Am. J. Physiol. 1995, 268, L699-L722.
106. Costell, M. H.; Ancellin, N.; Bernard, R. E.; Zhao, S.; Upson, J. J.; Morgan, L. A.; Maniscalco, K.; Olzinski, A. R.; Ballard, V. L.; Herry, K.; et al. Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress. Front. Pharmacol. 2012, 3, 128.
107. Gheorghiade, M.; Marti, C. N.; Sabbah, H. N.; Roessig, L.; Greene, S. J.; Böhm, M.; Burnett, J. C.; Campia, U.; Cleland, J. G.; Collins, S. P.; et al. Academic Research Team in Heart Failure (ART-HF). Soluble guanylate cyclase: A potential therapeutic target for heart failure. Heart Fail. Rev. 2013, 18, 123-134.
108. Irvine, J. C.; Ganthavee, V.; Love, J. E.; Alexander, A. E.; Horowitz, J. D.; Stasch, J. P.; Kemp-Harper, B. K.; Ritchie, R. H. The soluble guanylyl cyclase activator bay 58-2667 selectively limits cardiomyocyte hypertrophy. PLoS One 2012, 7, e44481.
109. Lin, E. Q.; Irvine, J. C.; Cao, A. H.; Alexander, A. E.; Love, J. E.; Patel, R.; McMullen, J. R.; Kaye, D. M.; Kemp-Harper, B. K.; Ritchie, R. H. Nitroxyl (HNO) stimulates soluble guanylyl cyclase to suppress cardiomyocyte hypertrophy and superoxide generation. PLoS One 2012, 7, e34892.
110. Blanton, R. M.; Takimoto, E.; Lane, A. M.; Aronovitz, M.; Piotrowski, R.; Karas, R. H.; Kass, D. A.; Mendelsohn, M. E. Protein kinase G Iα inhibits pressure overload-induced cardiac remodeling and is required for the cardioprotective effect of sildenafil in vivo. J. Am. Heart Assoc. 2012, 1, e003731.
111. Westermann, D.; Becher, P. M.; Lindner, D.; Savvatis, K.; Xia, Y.; Fröhlich, M.; Hoffmann, S.; Schultheiss, H. P.; Tschöpe, C. Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo. Basic Res. Cardiol. 2012, 107, 308.
112. Crassous, P. A.; Couloubaly, S.; Huang, C.; Zhou, Z.; Baskaran, P.; Kim, D. D.; Papapetropoulos, A.; Fioramonti, X.; Durán, W. N.; Beuve, A. Soluble guanylyl cyclase is a target of angiotensin II-induced nitrosative stress in a hypertensive rat model. Am. J. Physiol. Heart Circ. Physiol. 2012, 303, H597-H604.
113. Schmidt, K.; Neubauer, A.; Kolesnik, B.; Stasch, J. P.; Werner, E. R.; Gorren, A. C.; Mayer, B. Tetrahydrobiopterin protects soluble guanylate cyclase against oxidative inactivation. Mol. Pharmacol. 2012, 82, 420-427.
114. Aggarwal, S.; Gross, C. M.; Kumar, S.; Datar, S.; Oishi, P.; Kalkan, G.; Schreiber, C.; Fratz, S.; Fineman, J. R.; Black, S. M. Attenuated vasodilatation in lambs with endogenous and exogenous activation of cGMP signaling: Role of protein kinase G nitration. J. Cell. Physiol. 2011, 226, 3104-3113.
115. Negash, S.; Gao, Y.; Zhou, W.; Liu, J.; Chinta, S.; Raj, J. U. Regulation of cGMP-dependent protein kinase-mediated vasodilation by hypoxia-induced reactive species in ovine fetal pulmonary veins. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 293, L1012-L1020.
116. Cruz, J. A.; Bauer, E. M.; Rodriguez, A. I.; Gangopadhyay, A.; Zeineh, N. S.; Wang, Y.; Shiva, S.; Champion, H. C.; Bauer, P. M. Chronic hypoxia induces right heart failure in caveolin-1-/-mice. Am. J. Physiol. Heart Circ. Physiol. 2012, 302, H2518-H2527.
117. Zhao, Y. Y.; Malik, A. B. A novel insight into the mechanism of pulmonary hypertension involving caveolin-1 deficiency and endothelial nitric oxide synthase activation. Trends Cardiovasc. Med. 2009, 19, 238-242.
118. Liu, Y.; Dillon, A. R.; Tillson, M.; Makarewich, C.; Nguyen, V.; Dell'italia, L.; Sabri, A. K.; Rizzo, V.; Tsai, E. J. Volume overload induces differential spatiotemporal regulation of myocardial soluble guanylyl cyclase in eccentric hypertrophy and heart failure. J. Mol. Cell. Cardiol. 2013, 60C, 72-83.
119. Lu, Z.; Xu, X.; Hu, X.; Lee, S.; Traverse, J. H.; Zhu, G.; Fassett, J.; Tao, Y.; Zhang, P.; dos Remedios, C.; et al. Oxidative stress regulates left ventricular PDE5 expression in the failing heart. Circulation 2010, 121, 1474-1483.
120. Takahashi, M.; Takeda, S.; Kurokawa, S.; Kubo, T.; Fukuda, N.; Izumi, T. Cyclic GMP production by ANP, BNP, and NO during worsening and improvement of chronic heart failure. Jpn. Heart J. 2003, 44, 713-724.
121. Woodard, G. E.; Rosado, J. A. Natriuretic peptides in vascular physiology and pathology. Int. Rev. Cell. Mol. Biol. 2008, 268, 59-93.
122. Dickey, D. M.; Flora, D. R.; Bryan, P. M.; Xu, X.; Chen, Y.; Potter, L. R. Differential regulation of membrane guanylyl cyclases in congestive heart failure: Natriuretic peptide receptor (NPR)-B, not NPR-A, is the predominant natriuretic peptide receptor in the failing heart. Endocrinology 2007, 148, 3518-3522.
123. Arstall, M. A.; Sawyer, D. B.; Fukazawa, R.; Kelly, R. A. Cytokine-mediated apoptosis in cardiac myocytes: The role of inducible nitric oxide synthase induction and peroxynitrite generation. Circ. Res. 1999, 85, 829-840.
124. Bayeva, M.; Gheorghiade, M.; Ardehali, H. Mitochondria as a therapeutic target in heart failure. J. Am. Coll. Cardiol. 2013, 61, 599-610.
125. Ventura-Clapier, R.; Garnier, A.; Veksler, V.; Joubert, F. Bioenergetics of the failing heart. Biochim. Biophys. Acta 2011, 1813, 1360-1372.
126. Casademont, J.; Miró, O. Electron transport chain defects in heart failure. Heart Fail. Rev. 2002, 7, 131-139.
127. Rosca, M. G.; Tandler, B.; Hoppel, C. L. Mitochondria in cardiac hypertrophy and heart failure. J. Mol. Cell. Cardiol. 2013, 55, 31-41.
128. Rosca, M. G.; Hoppel, C. L. Mitochondria in heart failure. Cardiovasc. Res. 2010, 88, 40-50.
129. Ventura-Clapier, R.; Garnier, A.; Veksler, V. Energy metabolism in heart failure. J. Physiol. 2004, 555, 1-13.
130. Verdejo, H. E.; del Campo, A.; Troncoso, R.; Gutierrez, T.; Toro, B.; Quiroga, C.; Pedrozo, Z.; Munoz, J. P.; Garcia, L.; Castro, P. F.; et al. Mitochondria, myocardial remodeling, and cardiovascular disease. Curr. Hypertens. Rep. 2012, 14, 532-539.
131. Scolletta, S.; Biagioli, B. Energetic myocardial metabolism and oxidative stress: Let's make them our friends in the fight against heart failure. Biomed. Pharmacother. 2010, 64, 203-207.
132. Jaswal, J. S.; Keung, W.; Wang, W.; Ussher, J. R.; Lopaschuk, G. D. Targeting fatty acid and carbohydrate oxidation-A novel therapeutic intervention in the ischemic and failing heart. Biochim. Biophys. Acta 2011 1813, 1333-1350.
133. Joiner, M. L.; Koval, O. M.; Li, J.; He, B. J.; Allamargot, C.; Gao, Z.; Luczak, E. D.; Hall, D. D.; Fink, B. D.; Chen, B.; et al. CaMKII determines mitochondrial stress responses in heart. Nature 2012, 491, 269-273.
134. Chen, Y.; Liu, Y.; Dorn, G. W., 2nd. Mitochondrial fusion is essential for organelle function and cardiac homeostasis. Circ. Res. 2011, 109, 1327-1331.
135. Hal, M. E.; Smith, G.; Hall, J. E.; Stec, D. E. Systolic dysfunction in cardiac-specific ligand-inducible MerCreMer transgenic mice. Am. J. Physiol. Heart Circ. Physiol. 2011, 301, H253-H260.
136. Shin, J.; Lee, S. H.; Kwon, M. C.; Yang, D. K.; Seo, H. R.; Kim, J.; Kim, Y. Y.; Im, S. K.; Abel, E. D.; Kim, K. T.; et al. Cardiomyocyte specific deletion of Crif1 causes mitochondrial cardiomyopathy in mice. PLoS One 2013, 8, e53577.
137. Ferrari, R.; Merli, E.; Cicchitelli, G.; Mele, D.; Fucili, A.; Ceconi, C. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: A review. Ann. N. Y. Acad. Sci. 2004, 1033, 79-91.
138. Mingorance, C.; Rodríguez-Rodríguez, R.; Justo, M. L.; Alvarez de Sotomayor, M.; Herrera, M. D. Pharmacological effects and clinical applications of propionyl-L-carnitine. Nutr. Rev. 2011, 69, 279-290.
139. Malaguarnera, M. Carnitine derivatives: Clinical usefulness. Curr. Opin. Gastroenterol. 2012, 28, 166-176.
140. Fotino, A. D.; Thompson-Paul, A. M.; Bazzano, L. A. Effect of coenzyme Q10 supplementation on heart failure: A meta-analysis. Am. J. Clin. Nutr. 2013, 97, 268-275.
141. Stocker, R.; Macdonald, P. The benefit of coenzyme Q10 supplements in the management of chronic heart failure: A long tale of promise in the continued absence of clear evidence. Am. J. Clin. Nutr. 2013, 97, 233-234.
142. Silberman, G. A.; Fan, T. H.; Liu, H.; Jiao, Z.; Xiao, H. D.; Lovelock, J. D.; Boulden, B. M.; Widder, J.; Fredd, S.; Bernstein, K. E.; et al. Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation 2010, 121, 519-528.
143. Takimoto, E.; Champion, H. C.; Li, M.; Ren, S.; Rodriguez, E. R.; Tavazzi, B.; Lazzarino, G.; Paolocci, N.; Gabrielson, K. L.; Wang, Y.; et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J. Clin. Investig. 2005, 115, 1221-1231.
144. Moens, A. L.; Takimoto, E.; Tocchetti, C. G.; Chakir, K.; Bedja, D.; Cormaci, G.; Ketner, E. A.; Majmudar, M.; Gabrielson, K.; Halushka, M. K.; et al. Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: Efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation 2008, 117, 2626-2636.
145. Jessup, J. A.; Zhang, L.; Chen, A. F.; Presley, T. D.; Kim-Shapiro, D. B.; Chappell, M. C.; Wang, H.; Groban, L. Neuronal nitric oxide synthase inhibition improves diastolic function and reduces oxidative stress in ovariectomized mRen2. Lewis rats. Menopause 2011, 18, 698-708.
146. Nishijima, Y.; Sridhar, A.; Bonilla, I.; Velayutham, M.; Khan, M.; Terentyeva, R.; Li, C.; Kuppusamy, P.; Elton, T. S.; Terentyev, D.; et al. Tetrahydrobiopterin depletion and NOS2 uncoupling contribute to heart failure-induced alterations in atrial electrophysiology. Cardiovasc. Res. 2011, 91, 71-79.
147. Crijns, H. J.; Schotten, U.; Moens, A. L. Is NOS uncoupling the missing link between atrial fibrillation and chronic non-ischaemic cardiomyopathy? Cardiovasc. Res. 2011, 91, 556.
148. Nishijima, Y.; Sridhar, A.; Zweier, J. L.; Cardounel, A. J.; Carnes, C. A. Is NOS uncoupling the missing link between atrial fibrillation and chronic non-ischaemic cardiomyopathy? Author reply. Cardiovasc. Res. 2011, 91, 557-558.
149. Alkaitis, M. S.; Crabtree, M. J. Recoupling of cardiac nitric oxide synthases: Tetrahydrobiopterin synthesis and recycling. Curr. Heart Fail. Rep. 2012, 9, 200-210.
150. Tang, W. H.; Shrestha, K.; Tong, W.; Wang, Z.; Troughton, R. W.; Borowski, A. G.; Klein, A. L.; Hazen, S. L. Nitric oxide bioavailability and adiponectin production in chronic systolic heart failure: Relation to severity of cardiac dysfunction. Transl. Res. 2013, 162, 26-33.
151. Xi, W.; Satoh, H.; Kase, H.; Suzuki, K.; Hattori, Y. Stimulated HSP90 binding to eNOS and activation of the PI3-Akt pathway contribute to globular adiponectin-induced NO production: Vasorelaxation in response to globular adiponectin. Biochem. Biophys. Res. Commun. 2005, 332, 200-205.
152. Lin, L. Y.; Lin, C. Y.; Su, T. C.; Liau, C. S. Angiotensin II-induced apoptosis in human endothelial cells is inhibited by adiponectin through restoration of the association between endothelial nitric oxide synthase and heat shock protein 90. FEBS Lett. 2004, 574, 106-110.
153. Pall, M. L. Do sauna therapy and exercise act by raising the availability of tetrahydrobiopterin? Med. Hypotheses 2009, 73, 610-613.
154. Wang, X.; Hattori, Y.; Satoh, H.; Iwata, C.; Banba, N.; Monden, T.; Uchida, K.; Kamikawa, Y.; Kasai, K. Tetrahydrobiopterin prevents endothelial dysfunction and restores adiponectin levels in rats. Eur. J. Pharmacol. 2007, 555, 48-53.
155. Sharma, S.; Sun, X.; Kumar, S.; Rafikov, R.; Aramburo, A.; Kalkan, G.; Tian, J.; Rehmani, I.; Kallarackal, S.; Fineman, J. R.; et al. Preserving mitochondrial function prevents the proteasomal degradation of GTP cyclohydrolase I. Free Radic. Biol. Med. 2012, 53, 216-229.
156. Morgan, J. P.; Erny, R. E.; Allen, P. D.; Grossman, W.; Gwathmey, J. K. Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure. Circulation 1990, 81, III21-III32.
157. Reuter, H.; Schwinger, R. H. Calcium handling in human heart failure-Abnormalities and target for therapy. Wien. Med. Wochenschr. 2012, 162, 297-301.
158. Marks, A. R. Calcium cycling proteins and heart failure: Mechanisms and therapeutics. J. Clin. Investig. 2013, 123, 46-52.
159. Knyushko, T. V.; Sharov, V. S.; Williams, T. D.; Schöneich, C.; Bigelow, D. J. 3-Nitrotyrosine modification of SERCA2a in the aging heart: A distinct signature of the cellular redox environment. Biochemistry 2005, 44, 13071-13081.
160. Squier, T. C.; Bigelow, D. J. Protein oxidation and age-dependent alterations in calcium homeostasis. Front. Biosci. 2000, 5, D504-D526.
161. 2+ channel. Mol. Pharmacol. 1998, 53, 497-503.
162. Salama, G.; Menshikova, E. V.; Abramson, J. J. Molecular interaction between nitric oxide and ryanodine receptors of skeletal and cardiac sarcoplasmic reticulum. Antioxid. Redox Signal. 2000, 2, 5-16.
163. Kanski, J.; Hong, S. J.; Schöneich, C. Proteomic analysis of protein nitration in aging skeletal muscle and identification of nitrotyrosine-containing sequences in vivo by nanoelectrospray ionization tandem mass spectrometry. J. Biol. Chem. 2005, 280, 24261-24266.
164. McCauley, M. D.; Wehrens, X. H. Targeting ryanodine receptors for anti-arrhythmic therapy. Acta Pharmacol. Sin. 2011, 32, 749-757.
165. Kho, C.; Lee, A.; Hajjar, R. J. Altered sarcoplasmic reticulum calcium cycling-Targets for heart failure therapy. Nat. Rev. Cardiol. 2012, 9, 717-733.
166. Currie, S.; Elliott, E. B.; Smith, G. L.; Loughrey, C. M. Two candidates at the heart of dysfunction: The ryanodine receptor and calcium/calmodulin protein kinase II as potential targets for therapeutic intervention-An in vivo perspective. Pharmacol. Ther. 2011, 131, 204-220.
167. Ahmad, H. A.; Lu, L.; Ye, S.; Schwartz, G. G.; Greyson, C. R. Calpain inhibition preserves talin and attenuates right heart failure in acute pulmonary hypertension. Am. J. Respir. Cell Mol. Biol. 2012, 47, 379-386.
168. Letavernier, E.; Zafrani, L.; Perez, J.; Letavernier, B.; Haymann, J. P.; Baud, L. The role of calpains in myocardial remodelling and heart failure. Cardiovasc. Res. 2012, 96, 38-45.
169. Campos, E. C.; O'Connell, J. L.; Malvestio, L. M.; Romano, M. M.; Ramos, S. G.; Celes, M. R.; Prado, C. M.; Simões, M. V.; Rossi, M. A. Calpain-mediated dystrophin disruption may be a potential structural culprit behind chronic doxorubicin-induced cardiomyopathy. Eur. J. Pharmacol. 2011, 670, 541-553.
170. Greyson, C. R.; Schwartz, G. G.; Lu, L.; Ye, S.; Helmke, S.; Xu, Y.; Ahmad, H. Calpain inhibition attenuates right ventricular contractile dysfunction after acute pressure overload. J. Mol. Cell. Cardiol. 2008, 44, 59-68.
171. Patterson, C.; Portbury, A. L.; Schisler, J. C.; Willis, M. S. Tear me down: Role of calpain in the development of cardiac ventricular hypertrophy. Circ. Res. 2011, 109, 453-462.
172. Li, X.; Li, Y.; Shan, L.; Shen, E.; Chen, R.; Peng, T. Over-expression of calpastatin inhibits calpain activation and attenuates myocardial dysfunction during endotoxaemia. Cardiovasc. Res. 2009, 83, 72-79.
173. Smith, M. A.; Schnellmann, R. G. Calpains, mitochondria, and apoptosis. Cardiovasc. Res. 2012, 96, 32-37.
174. Bukowska, A.; Lendeckel, U.; Bode-Böger, S. M.; Goette, A. Physiologic and pathophysiologic role of calpain: Implications for the occurrence of atrial fibrillation. Cardiovasc. Ther. 2012, 30, e115-e127.
175. Mani, S. K.; Shiraishi, H.; Balasubramanian, S.; Yamane, K.; Chellaiah, M.; Cooper, G.; Banik, N.; Zile, M. R.; Kuppuswamy, D. In vivo administration of calpeptin attenuates calpain activation and cardiomyocyte loss in pressure-overloaded feline myocardium. Am. J. Physiol. Heart Circ. Physiol. 2008, 295, H314-H326.
176. Wang, J. C.; Zhao, Y.; Li, X. D.; Zhou, N. N.; Sun, H.; Sun, Y. Y. Proteolysis by endogenous calpain I leads to the activation of calcineurin in human heart. Clin. Lab. 2012, 58, 1145-1152.
177. Ashpole, N. M.; Herren, A. W.; Ginsburg, K. S.; Brogan, J. D.; Johnson, D. E.; Cummins, T. R.; Bers, D. M.; Hudmon, A. Ca2+/calmodulin-dependent protein kinase II (CaMKII) regulates cardiac sodium channel NaV1. 5 gating by multiple phosphorylation sites. J. Biol. Chem. 2012, 287, 19856-19869.
178. Hamdani, N.; Krysiak, J.; Kreusser, M. M.; Neef, S.; Dos Remedios, C. G.; Maier, L. S.; Krüger, M.; Backs, J.; Linke, W. A. Crucial role for Ca2+/calmodulin-dependent protein kinase-II in regulating diastolic stress of normal and failing hearts via titin phosphorylation. Circ. Res. 2013, 112, 664-674.
179. 2+ leak. J. Mol. Cell. Cardiol. 2013, 56, 34-43.
180. Fischer, T. H.; Neef, S.; Maier, L. S. The Ca-calmodulin dependent kinase II: A promising target for future antiarrhythmic therapies? J. Mol. Cell. Cardiol. 2013, 58, 182-187.
181. Wilkins, B. J.; Dai, Y. S.; Bueno, O. F.; Parsons, S. A.; Xu, J.; Plank, D. M.; Jones, F.; Kimball, T. R.; Molkentin, J. D. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ. Res. 2004, 94, 110-118.
182. Prévilon, M.; Pezet, M.; Dachez, C.; Mercadier, J. J.; Rouet-Benzineb, P. Sequential alterations in Akt, GSK3β, and calcineurin signalling in the mouse left ventricle after thoracic aortic constriction. Can. J. Physiol. Pharmacol. 2010, 88, 1093-1101.
183. Chen, Q. Q.; Zhang, W.; Chen, X. F.; Bao, Y. J.; Wang, J.; Zhu, W. Z. Electrical field stimulation induces cardiac fibroblast proliferation through the calcineurin-NFAT pathway. Can. J. Physiol. Pharmacol. 2012, 90, 1611-1622.
184. Berry, J. M.; Le, V.; Rotter, D.; Battiprolu, P. K.; Grinsfelder, B.; Tannous, P.; Burchfield, J. S.; Czubryt, M.; Backs, J.; Olson, E. N.; et al. Reversibility of adverse, calcineurin-dependent cardiac remodeling. Circ. Res. 2011, 109, 407-417.
185. Lunde, I. G.; Kvaløy, H.; Austbø, B.; Christensen, G.; Carlson, C. R. Angiotensin II and norepinephrine activate specific calcineurin-dependent NFAT transcription factor isoforms in cardiomyocytes. J. Appl. Physiol. 2011, 111, 1278-1289.
186. Huang, C. F.; Su, M. J. Positive inotropic action of NMDA receptor antagonist (+)-MK801 in rat heart. J. Biomed. Sci. 1999, 6, 387-398.
187. Matsuoka, N.; Kodama, H.; Arakawa, H.; Yamaguchi, I. N-Methyl-D-aspartate receptor blockade by dizocilpine prevents stress-induced sudden death in cardiomyopathic hamsters. Brain Res. 2002, 944, 200-204.
188. Moshal, K. S.; Tipparaju, S. M.; Vacek, T. P.; Kumar, M.; Singh, M.; Frank, I. E.; Patibandla, P. K.; Tyagi, N.; Rai, J.; Metreveli, N.; et al. Mitochondrial matrix metalloproteinase activation decreases myocyte contractility in hyperhomocysteinemia. Am. J. Physiol. Heart Circ. Physiol. 2008, 295, H890-H897.
189. Moshal, K. S.; Kumar, M.; Tyagi, N.; Mishra, P. K.; Metreveli, N.; Rodriguez, W. E.; Tyagi, S. C. Restoration of contractility in hyperhomocysteinemia by cardiac-specific deletion of NMDA-R1. Am. J. Physiol. Heart Circ. Physiol. 2009, 296, H887-H892.
190. Moshal, K. S.; Metreveli, N.; Frank, I.; Tyagi, S. C. Mitochondrial MMP activation, dysfunction and arrhythmogenesis in hyperhomocysteinemia. Curr. Vasc. Pharmacol. 2008, 6, 84-92.
191. Maldonado, C.; Soni, C. V.; Todnem, N. D.; Pushpakumar, S.; Rosenberger, D.; Givvimani, S.; Villafane, J.; Tyagi, S. C. Hyperhomocysteinemia and sudden cardiac death: Potential arrhythmogenic mechanisms. Curr. Vasc. Pharmacol. 2010, 8, 64-74.
192. Gao, X.; Xu, X.; Pang, J.; Zhang, C.; Ding, J. M.; Peng, X.; Liu, Y.; Cao, J. M. NMDA receptor activation induces mitochondrial dysfunction, oxidative stress and apoptosis in cultured neonatal rat cardiomyocytes. Physiol. Res. 2007, 56, 559-569.
193. Tejero-Taldo, M. I.; Kramer, J. H.; Mak, I. T.; Komarov, A. M.; Weglicki, W. B. The nerve-heart connection in the pro-oxidant response to Mg-deficiency. Heart Fail. Rev. 2006, 11, 35-44.
194. Kreuder, C.; Miller, M. A.; Lowenstine, L. J.; Conrad, P. A.; Carpenter, T. E.; Jessup, D. A.; Mazet, J. A. Evaluation of cardiac lesions and risk factors associated with myocarditis and dilated cardiomyopathy in southern sea otters (Enhydra lutris nereis). Am. J. Vet. Res. 2005, 66, 289-299.
195. Rowell, J.; Koitabashi, N.; Kass, D. A. TRP-ing up heart and vessels: Canonical transient receptor potential channels and cardiovascular disease. J. Cardiovasc. Transl. Res. 2010, 3, 516-524.
196. Watanabe, H.; Murakami, M.; Ohba, T.; Takahashi, Y.; Ito, H. TRP channel and cardiovascular disease. Pharmacol. Ther. 2008, 118, 337-351.
197. Stiber, J. A.; Tang, Y.; Li, T.; Rosenberg, P. B. Cytoskeletal regulation of TRPC channels in the cardiorenal system. Curr. Hypertens. Rep. 2012, 14, 492-497.
198. Hirose, M.; Takeishi, Y.; Niizeki, T.; Nakada, T.; Shimojo, H.; Kashihara, T.; Horiuchi-Hirose, M.; Kubota, I.; Mende, U.; Yamada, M. Diacylglycerol kinase ζ inhibits ventricular tachyarrhythmias in a mouse model of heart failure. Circ. J. 2011, 75, 2333-2342.
199. Kuwahara, K.; Wang, Y.; McAnally, J.; Richardson, J. A.; Bassel-Duby, R.; Hill, J. A.; Olson, E. N. TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. J. Clin. Investig. 2006, 116, 3114-3126.
200. Poteser, M.; Schleifer, H.; Lichtenegger, M.; Schernthaner, M.; Stockner, T.; Kappe, C. O.; Glasnov, T. N.; Romanin, C.; Groschner, K. PKC-dependent coupling of calcium permeation through transient receptor potential canonical 3 (TRPC3) to calcineurin signaling in HL-1 myocytes. Proc. Natl. Acad. Sci. USA 2011, 108, 10556-10561.
201. Bush, E. W.; Hood, D. B.; Papst, P. J.; Chapo, J. A.; Minobe, W.; Bristow, M. R.; Olson, E. N.; McKinsey, T. A. Canonical transient receptor potential channels promote cardiomyocyte hypertrophy through activation of calcineurin signaling. J. Biol. Chem. 2006, 281, 33487-33496.
202. Onohara, N.; Nishida, M.; Inoue, R.; Kobayashi, H.; Sumimoto, H.; Sato, Y.; Mori, Y.; Nagao, T.; Kurose, H. TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophy. EMBO J. 2006, 25, 5305-5316.
203. Nakayama, H.; Wilkin, B. J.; Bodi, I.; Molkentin, J. D. Calcineurin-dependent cardiomyopathy is activated by TRPC in the adult mouse heart. FASEB J. 2006, 20, 1660-1670.
204. Wu, X.; Eder, P.; Chang, B.; Molkentin, J. D. TRPC channels are necessary mediators of pathologic cardiac hypertrophy. Proc. Natl. Acad. Sci. USA 2010, 107, 7000-7005.
205. Seth, M.; Zhang, Z. S.; Mao, L.; Graham, V.; Burch, J.; Stiber, J.; Tsiokas, L.; Winn, M.; Abramowitz, J.; Rockman, H. A.; et al. TRPC1 channels are critical for hypertrophic signaling in the heart. Circ. Res. 2009, 105, 1023-1030.
206. Simard, C.; Sallé, L.; Rouet, R.; Guinamard, R. Transient receptor potential melastatin 4 inhibitor 9-phenanthrol abolishes arrhythmias induced by hypoxia and re-oxygenation in mouse ventricle. Br. J. Pharmacol. 2012, 165, 2354-2364.
207. Hazari, M. S.; Haykal-Coates, N.; Winsett, D. W.; Krantz, Q. T.; King, C.; Costa, D. L.; Farraj, A. K. TRPA1 and sympathetic activation contribute to increased risk of triggered cardiac arrhythmias in hypertensive rats exposed to diesel exhaust. Environ. Health Perspect. 2011, 119, 951-957.
208. Carll, A. P.; Hazari, M. S.; Perez, C. M.; Krantz, Q. T.; King, C. J.; Winsett, D. W.; Costa, D. L.; Farraj, A. K. Whole and particle-free diesel exhausts differentially affect cardiac electrophysiology, blood pressure, and autonomic balance in heart failure-prone rats. Toxicol. Sci. 2012, 128, 490-499.
209. Shaheen, M.; Cheema, Y.; Shahbaz, A. U.; Bhattacharya, S. K.; Weber, K. T. Intracellular calcium overloading and oxidative stress in cardiomyocyte necrosis via a mitochondriocentric signal-transducer-effector pathway. Exp. Clin. Cardiol. 2011, 16, 109-115.
210. 2+ channels in endothelin-1 function. Cell. Signal. 2005, 17, 911-916.
211. Sayen, M. R.; Gustaffsson, A. B.; Sussman, M. A.; Molkentin, J. D.; Gottlieb, R. A. Calcineurin transgenic mice have mitochondrial dysfunction and elevated superoxide production. Am. J. Physiol. Cell Physiol. 2003, 284, C562-C570.
212. Bachmaier, K.; Neu, N.; Pummerer, C.; Duncan, G. S.; Mak, T. W.; Matsuyama, T.; Penninger, J. M. iNOS expression and nitrotyrosine formation in the myocardium in response to inflammation is controlled by the interferon regulatory factor 1. Circulation 1997, 96, 585-591.
213. Glück, B.; Merkle, I.; Dornberger, G.; Stelzner, A. Expression of inducible nitric oxide synthase in experimental viral myocarditis. Herz 2000, 25, 255-260.
214. Mosqueira, M.; Zeiger, U.; Förderer, M.; Brinkmeier, H.; Fink, R. H. Cardiac and respiratory dysfunction in duchenne muscular dystrophy and the role of second messengers. Med. Res. Rev. 2013, 33, 1174-1213.
215. Judge, D. P.; Kass, D. A.; Thompson, W. R.; Wagner, K. R. Pathophysiology and therapy of cardiac dysfunction in Duchenne muscular dystrophy. Am. J. Cardiovasc. Drugs 2011, 11, 287-294.
216. Burelle, Y.; Khairallah, M.; Ascah, A.; Allen, B. G.; Deschepper, C. F.; Petrof, B. J.; Des Rosiers, C. Alterations in mitochondrial function as a harbinger of cardiomyopathy: Lessons from the dystrophic heart. J. Mol. Cell. Cardiol. 2010, 48, 310-321.
217. An, J.; Du, J.; Wei, N.; Guan, T.; Camara, A. K.; Shi, Y. Differential sensitivity to LPS-induced myocardial dysfunction in the isolated brown Norway and Dahl S rat hearts: Roles of mitochondrial function, NF-κB activation, and TNF-α production. Shock 2012, 37, 325-332.
218. Stamm, C.; Cowan, D. B.; Friehs, I.; Noria, S.; del Nido, P. J.; McGowan, F. X., Jr. Rapid endotoxin-induced alterations in myocardial calcium handling: Obligatory role of cardiac TNF-alpha. Anesthesiology 2001, 95, 1396-1405.
219. Matsuno, K.; Iwata, K.; Matsumoto, M.; Katsuyama, M.; Cui, W.; Murata, A.; Nakamura, H.; Ibi, M.; Ikami, K.; Zhang, J.; et al. NOX1/NADPH oxidase is involved in endotoxin-induced cardiomyocyte apoptosis. Free Radic. Biol. Med. 2012, 53, 1718-1728.
220. Lorigados, C. B.; Soriano, F. G.; Szabo, C. Pathomechanisms of myocardial dysfunction in sepsis. Endocr. Metab. Immune Disord. Drug Targets 2010, 10, 274-284.
221. Flesch, M.; Kilter, H.; Cremers, B.; Laufs, U.; Südkamp, M.; Ortmann, M.; Müller, F. U.; Böhm, M. Effects of endotoxin on human myocardial contractility involvement of nitric oxide and peroxynitrite. J. Am. Coll. Cardiol. 1999, 33, 1062-1070.
222. Alvarez, S.; Boveris, A. Mitochondrial nitric oxide metabolism in rat muscle during endotoxemia. Free Radic. Biol. Med. 2004, 37, 1472-1478.
223. Shiroshita-Takeshita, A.; Brundel, B. J.; Burstein, B.; Leung, T. K.; Mitamura, H.; Ogawa, S.; Nattel, S. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc. Res. 2007, 74, 75-84.
224. Pepe, M.; Mamdani, M.; Zentilin, L.; Csiszar, A.; Qanud, K.; Zacchigna, S.; Ungvari, Z.; Puligadda, U.; Moimas, S.; Xu, X.; et al. Intramyocardial VEGF-B167 gene delivery delays the progression towards congestive failure in dogs with pacing-induced dilated cardiomyopathy. Circ. Res. 2010, 106, 1893-1903.
225. Sachse, F. B.; Torres, N. S.; Savio-Galimberti, E.; Aiba, T.; Kass, D. A.; Tomaselli, G. F.; Bridge, J. H. Subcellular structures and function of myocytes impaired during heart failure are restored by cardiac resynchronization therapy. Circ. Res. 2012, 110, 588-597.
226. Liu, Y. H.; Carretero, O. A.; Cingolani, O. H.; Liao, T. D.; Sun, Y.; Xu, J.; Li, L. Y.; Pagano, P. J.; Yang, J. J.; Yang, X. P. Role of inducible nitric oxide synthase in cardiac function and remodeling in mice with heart failure due to myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 2005, 289, H2616-H2623.
227. Biondi, B. Mechanisms in endocrinology: Heart failure and thyroid dysfunction. Eur. J. Endocrinol. 2012, 167, 609-618.
228. Schmidt-Ott, U. M.; Ascheim, D. D. Thyroid hormone and heart failure. Curr. Heart Fail. Rep. 2006, 3, 114-119.
229. Athéa, Y.; Garnier, A.; Fortin, D.; Bahi, L.; Veksler, V.; Ventura-Clapier, R. Mitochondrial and energetic cardiac phenotype in hypothyroid rat. Relevance to heart failure. Pflugers Arch. 2007, 455, 431-442.
230. Papanas, N.; Papatheodorou, K.; Papazoglou, D.; Gioka, T.; Antonoglou, C.; Kotsiou, S.; Maltezos, E. Post-thyroidectomy thyroxine replacement dose in patients with or without compensated heart failure: The role of cytokines. Cytokine 2008, 41, 121-126.
231. Asayama, K.; Dobashi, K.; Hayashibe, H.; Megata, Y.; Kato, K. Lipid peroxidation and free radical scavengers in thyroid dysfunction in the rat: A possible mechanism of injury to heart and skeletal muscle in hyperthyroidism. Endocrinology 1987, 121, 2112-2118.
232. Callas, G.; Hayes, J. R. Alterations in the fine structure of cardiac muscle mitochondria induced by hyperthyroidism. Anat. Rec. 1974, 178, 539-549.
233. Liu, X.; Ye, B.; Miller, S.; Yuan, H.; Zhang, H.; Tian, L.; Nie, J.; Imae, R.; Arai, H.; Li, Y.; et al. Ablation of ALCAT1 mitigates hypertrophic cardiomyopathy through effects on oxidative stress and mitophagy. Mol. Cell. Biol. 2012, 32, 4493-4504.
234. Boehm, E. A.; Jones, B. E.; Radda, G. K.; Veech, R. L.; Clarke, K. Increased uncoupling proteins and decreased efficiency in palmitate-perfused hyperthyroid rat heart. Am. J. Physiol. Heart Circ. Physiol. 2001, 280, H977-H983.
235. Roman-Campos, D.; Sales-Júnior, P.; Duarte, H. L.; Gomes, E. R.; Guatimosim, S.; Ropert, C.; Gazzinelli, R. T.; Cruz, J. S. Cardiomyocyte dysfunction during the chronic phase of Chagas disease. Mem. Inst. Oswaldo Cruz 2013, 108, 243-245.
236. Báez, A. L.; Lo Presti, M. S.; Fretes, R.; Díaz, C.; Pons, P.; Bazán, P. C.; Strauss, M.; Rivarola, H. W.; Paglini-Oliva, P. Chronic indeterminate phase of Chagas' disease: Mitochondrial involvement in infection with two strains. Parasitology 2013, 140, 414-421.
237. Roman-Campos, D.; Sales-Junior, P.; Duarte, H. L.; Gomes, E. R.; Lara, A.; Campos, P.; Rocha, N. N.; Resende, R. R.; Ferreira, A.; Guatimosim, S.; et al. Novel insights into the development of chagasic cardiomyopathy: Role of PI3Kinase/NO axis. Int. J. Cardiol. 2013, 167, 3011-3020.
238. Rocha Rodrigues, D. B.; dos Reis, M. A.; Romano, A.; de Lima Pereira, S. A.; de Paula Autunes Teixeira, V.; Tostes, S., Jr.; Rodrigues, V., Jr. In situ expression of regulatory cytokines by heart inflammatory cells in Chagas' disease patients with heart failure. Clin. Dev. Immunol. 2012, 2012, 361730: 1-361730: 7.
239. Teixeira, P. C.; Santos, R. H.; Fiorelli, A. I.; Bilate, A. M.; Benvenuti, L. A.; Stolf, N. A.; Kalil, J.; Cunha-Neto, E. Selective decrease of components of the creatine kinase system and ATP synthase complex in chronic Chagas disease cardiomyopathy. PLoS Negl. Trop. Dis. 2011, 5, e1205.
240. Teixeira, P. C.; Iwai, L. K.; Kuramoto, A. C.; Honorato, R.; Fiorelli, A.; Stolf, N.; Kalil, J.; Cunha-Neto, E. Proteomic inventory of myocardial proteins from patients with chronic Chagas' cardiomyopathy. Braz. J. Med. Biol. Res. 2006, 39, 1549-1562.
241. Hosseinzadeh, L.; Behravan, J.; Mosaffa, F.; Bahrami, G.; Bahrami, A.; Karimi, G. Curcumin potentiates doxorubicin-induced apoptosis in H9c2 cardiac muscle cells through generation of reactive oxygen species. Food Chem. Toxicol. 2011, 49, 1102-1109.
242. Liu, C.; Cao, F.; Tang, Q. Z.; Yan, L.; Dong, Y. G.; Zhu, L. H.; Wang, L.; Bian, Z. Y.; Li, H. Allicin protects against cardiac hypertrophy and fibrosis via attenuating reactive oxygen species-dependent signaling pathways. J. Nutr. Biochem. 2010, 21, 1238-1250.
243. Gao, G.; Dudley, S. C., Jr. Redox regulation, NF-kappaB, and atrial fibrillation. Antioxid. Redox Signal. 2009, 11, 2265-2277.
244. Ueland, T.; Yndestad, A.; Dahl, C. P.; Gullestad, L.; Aukrust, P. TNF revisited: Osteoprotegerin and TNF-related molecules in heart failure. Curr. Heart Fail. Rep. 2012, 9, 92-100.
245. Alvarez-Guardia, D.; Palomer, X.; Coll, T.; Davidson, M. M.; Chan, T. O.; Feldman, A. M.; Laguna, J. C.; Vázquez-Carrera, M. The p65 subunit of NF-kappaB binds to PGC-1alpha, linking inflammation and metabolic disturbances in cardiac cells. Cardiovasc. Res. 2010, 87, 449-458.
246. Bartha, E.; Solti, I.; Szabo, A.; Olah, G.; Magyar, K.; Szabados, E.; Kalai, T.; Hideg, K.; Toth, K.; Gero, D.; et al. Regulation of kinase cascade activation and heat shock protein expression by poly(ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure. J. Cardiovasc. Pharmacol. 2011, 58, 380-391.
247. Bartha, E.; Kiss, G. N.; Kalman, E.; Kulcsár, G.; Kálai, T.; Hideg, K.; Habon, T.; Sumegi, B.; Toth, K.; Halmosi, R. Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure. J. Cardiovasc. Pharmacol. 2008, 52, 253-261.
248. Geng, B.; Cai, Y.; Gao, S.; Lu, J.; Zhang, L.; Zou, J.; Liu, M.; Yu, S.; Ye, J.; Liu, P. PARP-2 knockdown protects cardiomyocytes from hypertrophy via activation of SIRT1. Biochem. Biophys. Res. Commun. 2013, 430, 944-950.
249. Xiao, C. Y.; Chen, M.; Zsengellér, Z.; Li, H.; Kiss, L.; Kollai, M.; Szabó, C. Poly(ADP-Ribose) polymerase promotes cardiac remodeling, contractile failure, and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure. J. Pharmacol. Exp. Ther. 2005, 312, 891-898.
250. Kuroda, J.; Ago, T.; Matsushima, S.; Zhai, P.; Schneider, M. D.; Sadoshima, J. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc. Natl. Acad. Sci. USA 2010, 107, 15565-15570.
251. Turakhia, S.; Venkatakrishnan, C. D.; Dunsmore, K.; Wong, H.; Kuppusamy, P.; Zweier, J. L.; Ilangovan, G. Doxorubicin-induced cardiotoxicity: Direct correlation of cardiac fibroblast and H9c2 cell survival and aconitase activity with heat shock protein 27. Am. J. Physiol. Heart Circ. Physiol. 2007, 293, H3111-H3121.
252. Tziomalos, K.; Hare, J. M. Role of xanthine oxidoreductase in cardiac nitroso-redox imbalance. Front. Biosci. 2009, 14, 237-262.
253. Yamamoto, E.; Kataoka, K.; Yamashita, T.; Tokutomi, Y.; Dong, Y. F.; Matsuba, S.; Ogawa, H.; Kim-Mitsuyama, S. Role of xanthine oxidoreductase in the reversal of diastolic heart failure by candesartan in the salt-sensitive hypertensive rat. Hypertension 2007, 50, 657-662.
254. Rehsia, N. S.; Dhalla, N. S. Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure. Heart Fail. Rev. 2010, 15, 85-101.
255. Drawnel, F. M.; Archer, C. R.; Roderick, H. L. The role of the paracrine/autocrine mediator endothelin-1 in regulation of cardiac contractility and growth. Br. J. Pharmacol. 2013, 168, 296-317.
256. Zarain-Herzberg, A.; Estrada-Avilés, R.; Fragoso-Medina, J. Regulation of sarco(endo)plasmic reticulum Ca2+-ATPase and calsequestrin gene expression in the heart. Can. J. Physiol. Pharmacol. 2012, 90, 1017-1028.
257. Murray, D. B.; Gardner, J. D.; Brower, G. L.; Janicki, J. S. Endothelin-1 mediates cardiac mast cell degranulation, matrix metalloproteinase activation, and myocardial remodeling in rats. Am. J. Physiol. Heart Circ. Physiol. 2004, 287, H2295-H2299.
258. Murray, D. B.; Gardner, J. D.; Brower, G. L.; Janicki, J. S. Effects of nonselective endothelin-1 receptor antagonism on cardiac mast cell-mediated ventricular remodeling in rats. Am. J. Physiol. Heart Circ. Physiol. 2008, 294, H1251-H1257.
259. Takefuji, M.; Wirth, A.; Lukasova, M.; Takefuji, S.; Boettger, T.; Braun, T.; Althoff, T.; Offermanns, S.; Wettschureck, N. G(13)-mediated signaling pathway is required for pressure overload-induced cardiac remodeling and heart failure. Circulation 2012, 126, 1972-1982.
260. Haack, K. K.; Gao, L.; Schiller, A. M.; Curry, P. L.; Pellegrino, P. R.; Zucker, I. H. Central Rho kinase inhibition restores baroreflex sensitivity and angiotensin II type 1 receptor protein imbalance in conscious rabbits with chronic heart failure. Hypertension 2013, 61, 723-729.
261. Dong, M.; Liao, J. K.; Fang, F.; Lee, A. P.; Yan, B. P.; Liu, M.; Yu, C. M. Increased Rho kinase activity in congestive heart failure. Eur. J. Heart Fail. 2012, 14, 965-973.
262. Surma, M.; Wei, L.; Shi, J. Rho kinase as a therapeutic target in cardiovascular disease. Future Cardiol. 2011, 7, 657-671.
263. Satoh, K.; Fukumoto, Y.; Shimokawa, H. Rho-kinase: Important new therapeutic target in cardiovascular diseases. Am. J. Physiol. Heart Circ. Physiol. 2011, 301, H287-H296.
264. Shi, J.; Zhang, L.; Wei, L. Rho-kinase in development and heart failure: Insights from genetic models. Pediatr. Cardiol. 2011, 32, 297-304.
265. Wang, N.; Guan, P.; Zhang, J. P.; Li, Y. Q.; Chang, Y. Z.; Shi, Z. H.; Wang, F. Y.; Chu, L. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses isoproterenol-induced heart failure in rats via JNK and ERK1/2 pathways. J. Cell. Biochem. 2011, 112, 1920-1929.
266. Wang, N.; Guan, P.; Zhang, J. P.; Chang, Y. Z.; Gu, L. J.; Hao, F. K.; Shi, Z. H.; Wang, F. Y.; Chu, L. Preventive effects of fasudil on adriamycin-induced cardiomyopathy: Possible involvement of inhibition of RhoA/ROCK pathway. Food Chem. Toxicol. 2011, 49, 2975-2982.
267. Zhao, X. S.; Pan, W.; Bekeredjian, R.; Shohet, R. V. Endogenous endothelin-1 is required for cardiomyocyte survival in vivo. Circulation 2006, 114, 830-837.
268. Schorlemmer, A.; Matter, M. L.; Shohet, R. V. Cardioprotective signaling by endothelin. Trends Cardiovasc. Med. 2008, 18, 233-239.
269. Brown, G. C.; Neher, J. J. Inflammatory neurodegeneration and mechanisms of microglial killing in neurons. Mol. Neurobiol. 2010, 41, 242-247.
270. Brown, G. C.; Bal-Price, A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol. Neurobiol. 2003, 27, 325-355.
271. Cole, R. T.; Kalogeropoulos, A. P.; Georgiopoulou, V. V.; Gheorghiade, M.; Quyyumi, A.; Yancy, C.; Butler, J. Hydralazine and isosorbide dinitrate in heart failure: Historical perspective, mechanisms, and future directions. Circulation 2011, 123, 2414-2422.
272. Arif, S. A.; Mergenhagen, K. A.; del Carpio, R. O.; Ho, C. Treatment of systolic heart failure in the elderly: An evidence-based review. Ann. Pharmacother. 2010, 44, 1604-1614.
273. Taylor, A. L.; Sabolinski, M. L.; Tam, S. W.; Ziesche, S.; Ghali, J. K.; Archambault, W. T.; Worcel, M.; Cohn, J. N.; A-HeFT Investigators. Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the African-American heart failure trial. J. Card. Fail. 2012, 18, 600-606.
274. Csiszar, A.; Labinskyy, N.; Podlutsky, A.; Kaminski, P. M.; Wolin, M. S.; Zhang, C.; Mukhopadhyay, P.; Pacher, P.; Hu, F.; de Cabo, R.; et al. Vasoprotective effects of resveratrol and SIRT1: Attenuation of cigarette smoke-induced oxidative stress and proinflammatory phenotypic alterations. Am. J. Physiol. Heart Circ. Physiol. 2008, 294, H2721-H2735.
275. Csiszar, A.; Labinskyy, N.; Jimenez, R.; Pinto, J. T.; Ballabh, P.; Losonczy, G.; Pearson, K. J.; de Cabo, R.; Ungvari, Z. Anti-oxidative and anti-inflammatory vasoprotective effects of caloric restriction in aging: Role of circulating factors and SIRT1. Mech. Ageing Dev. 2009, 130, 518-527.
276. Huang, W.; Shang, W. L.; Wang, H. D.; Wu, W. W.; Hou, S. X. Sirt1 overexpression protects murine osteoblasts against TNF-α-induced injury in vitro by suppressing the NF-κB signaling pathway. Acta Pharmacol. Sin. 2012, 33, 668-674.
277. Xia, N.; Daiber, A.; Habermeier, A.; Closs, E. I.; Thum, T.; Spanier, G.; Lu, Q.; Oelze, M.; Torzewski, M.; Lackner, K. J.; et al. Resveratrol reverses endothelial nitric-oxide synthase uncoupling in apolipoprotein E knockout mice. J. Pharmacol. Exp. Ther. 2010, 335, 149-154.
278. Ungvari, Z.; Labinskyy, N.; Mukhopadhyay, P.; Pinto, J. T.; Bagi, Z.; Ballabh, P.; Zhang, C.; Pacher, P.; Csiszar, A. Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2009, 297, H1876-H1881.
279. Biala, A.; Tauriainen, E.; Siltanen, A.; Shi, J.; Merasto, S.; Louhelainen, M.; Martonen, E.; Finckenberg, P.; Muller, D. N.; Mervaala, E. Resveratrol induces mitochondrial biogenesis and ameliorates Ang II-induced cardiac remodeling in transgenic rats harboring human renin and angiotensinogen genes. Blood Press. 2010, 19, 196-205.
280. Tsai, R. Y.; Chou, K, Y.; Shen, C. H.; Chien, C. C.; Tsai, W. Y.; Huang, Y. N.; Tao, P. L.; Lin, Y. S.; Wong, C. S. Resveratrol regulates N-methyl-D-aspartate receptor expression and suppresses neuroinflammation in morphine-tolerant rats. Anesth. Analg. 2012, 115, 944-952.
281. Quincozes-Santos, A.; Gottfried, C. Resveratrol modulates astroglial functions: Neuroprotective hypothesis. Ann. N. Y. Acad. Sci. 2011, 1215, 72-78.
282. Chung, S.; Yao, H.; Caito, S.; Hwang, J. W.; Arunachalam, G.; Rahman, I. Regulation of SIRT1 in cellular functions: Role of polyphenols. Arch. Biochem. Biophys. 2010, 501, 79-90.
283. Nadtochiy, S. M.; Yao, H.; McBurney, M. W.; Gu, W.; Guarente, L.; Rahman, I.; Brookes, P. S. SIRT1-mediated acute cardioprotection. Am. J. Physiol. Heart Circ. Physiol. 2011, 301, H1506-H1512.
284. Sundaresan, N. R.; Pillai, V. B.; Gupta, M. P. Emerging roles of SIRT1 deacetylase in regulating cardiomyocyte survival and hypertrophy. J. Mol. Cell. Cardiol. 2011, 51, 614-618.